Detalhe da pesquisa
1.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Lancet Oncol
; 23(7): 851-864, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671774
2.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 21(3): 345-357, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32035020
3.
Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.
Lancet Oncol
; 21(5): e234, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359499